BRIEF—Pharma backing helps Rewind to raise 15.2 million euros

Rewind Therapeutics, a privately-held Belgian biotech, has completed a 15.2 million euros ($18.3 million) Series A financing to advance its development of re-myelinating therapies for multiple sclerosis and other myelin-related diseases.

The round was led by Boehringer Ingelheim Venture Fund (BIVF), Merck Ventures, the venture capital arms of two German pharma companies, along with Participatiemaatschappij Vlaanderen, KU Leuven’s Centre for Drug Design and Discovery and KU Leuven Gemma Frisius Fonds.

Rewind will use the proceeds to bring its proprietary first small molecule product to the clinic and to further expand its pipeline of novel drug candidates targeting myelin disorders.